-
Editorial Team
Posts
Oligomerix to Present at BIO CEO & Investor Conference, TAU2020 Global Conference
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that...
Targeting Amyloid Oligomers for Alzheimer’s Research
Alzheimer’s disease is one of the most frightening diseases people can face. The deterioration of memory and comprehension and, ultimately death, is a terrifying concept....
BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced...
Salk scientists link rapid brain growth in autism to DNA damage
LA JOLLA–(January 30, 2020) Researchers at the Salk Institute have discovered a unique pattern of DNA damage that arises in brain cells derived from individuals...
BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
Bausch Health Companies (BHC) Receives a Buy from Barclays
In a report issued on January 24, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research Report), with a price target of $33.00. The company’s...
Research Drug ‘chaperone’ fends off Alzheimer’s in mice by preventing toxic protein clumping
Alzheimer’s disease has long been associated with the harmful proteins amyloid beta and tau. They clump up in the brain, disrupting neurons and causing memory...
GLOBAL HIRUDIN PRODUCTS MARKET 2020 – THE MEDICINES COMPANY, TEVA PHARMACEUTICAL INDUSTRIES LTD, PFIZER, INC
The Global Hirudin Products Market report Interpretes the complete details covering Executive summary, Scope of the report, Research Methodology, Introduction, Market landscape, Market segmentation by type, Segmentation...
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion
– The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and...
Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain
“This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans,” wrote Jonathan Kipnis of University...